Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors

Journal of Clinical Oncology

Volumn 31, Issue 2, 2013, Pages

  Fangusaro, Jason ^a   Gururangan, Sridharan ^b   Jakacki, Regina I ^c   Kaste, Sue C ^d   Goldman, Stewart ^a   Pollack, Ian F ^c   Boyett, James M ^e   Kun, Larry E ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e Biostatistics Shared Resource for the St Jude Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; HYDROCORTISONE; STEROID;

ADOLESCENT; ARTICLE; AVASCULAR NECROSIS; BONE MARROW EDEMA; BONE NECROSIS; BONE PAIN; BONE RADIOGRAPHY; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPENDYMOMA; EPIPHYSIS; FEMALE; FEMUR CONDYLE; FOLLOW UP; HUMAN; KIENBOECK DISEASE; KNEE; KNEE PAIN; LUNATE BONE; MALE; METAPHYSIS; MUSCULOSKELETAL PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSCLEROSIS; PALPATION; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; RANGE OF MOTION; SCHOOL CHILD; STEROID THERAPY; TREATMENT DURATION; TUMOR GROWTH; TUMOR RECURRENCE; WRIST; WRIST PAIN; WRIST RADIOGRAPHY;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; FEMALE; HUMANS; KNEE JOINT; MALE; OSTEONECROSIS; WRIST;

EID: 84872512715     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6733     Document Type: Article

References (32)

1. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002
2. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002
3. Glade-Bender J, Kandel JJ, Yamashiro DJ: VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3: 263-276, 2003
4. Hinoda Y, Sasaki S, Ishida T, et al: Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95: 621-625, 2004
5. Zondor SD, Medina PJ: Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 38: 1258-1264, 2004
6. Glade Bender JL, Adamson PC, Reid JM, et al: Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 26: 399-405, 2008
7. André N, Verschuur A, Rossler J, et al: Anti-angiogenic therapies for children with cancer. Curr Cancer Drug Targets 10: 879-889, 2010
8. Taylor M, Rössler J, Geoerger B, et al: New anti-angiogenic strategies in pediatric solid malignancies: Agents and biomarkers of a near future. Expert Opin Investig Drugs 19: 859-874, 2010
9. Ferrara N, Hillan KJ, Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335, 2005
10. Lin YS, Nguyen C, Mendoza JL, et al: Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288: 371-378, 1999
11. Yuan F, Chen Y, Dellian M, et al: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93: 14765-14770, 1996
12. Salort-Llorca C, Mínguez-Serra MP, Silvestre-Donat FJ: Maxillary osteonecrosis associated to antiangiogenic drugs. Med Oral Patol Oral Cir Bucal 16:e137-8, 2011
13. Bagan J, Scully C, Sabater V, et al: Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol 45: 551-554, 2009
14. Mirzai R, Chang C, Greenspan A, et al: The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma 36: 77-95, 1999
15. Han JW: Bisphosphonate related osteonecrosis of the jaws: Report of two cases. Imaging Sci Dent 41: 129-134, 2011
16. Kos M, Kuebler JF, Luczak K, et al: Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 38: 255-259, 2010
17. Francini F, Pascucci A, Francini E, et al: Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. J Am Dent Assoc 142: 506-513, 2011
18. Ngamphaiboon N, Frustino JL, Kossoff EB, et al: Osteonecrosis of the jaw: Dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Clin Breast Cancer 11: 252-257, 2011
19. Dişel U, Beşen AA,ÖzyilkanÖ, et al: A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit. Oral Oncol 48:e2-e3, 2012
20. Hopp RN, Pucci J, Santos-Silva AR, et al: Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg 70: 632-635, 2012
21. Christodoulou C, Pervena A, Klouvas G, et al: Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76: 209-211, 2009
22. Mir O, Coriat R, Gregory T, et al: Avascular necrosis of the femoral head: A rare class-effect of anti-VEGF agents. Invest New Drugs 29: 716-718, 2011
23. Koczywas M, Cristea MC: Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 6:1960- 1961, 2011
24. Guillet M, Walter T, Scoazec JY, et al: Sorafenib-induced bilateral osteonecrosis of femoral heads. J Clin Oncol 28:e14, 2010
25. Ryan AM, Eppler DB, Hagler KE, et al: Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27: 78-86, 1999
26. Shih T, Lindley C: Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28: 1779-1802, 2006
27. Katsenos S, Christophylakis C, Psathakis K: Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab. Arch Bronconeumol 48: 218-219, 2012
28. Wynn RL: Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw. Gen Dent 59: 410-413, 2011
29. Van Poznak C: Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 122: 189-191, 2010
30. Smith AR, Hennessy JM, Kurth MA, et al: Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome. Pediatr Blood Cancer 51: 418-420, 2008
31. Estilo CL, Fornier M, Farooki A, et al: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26: 4037-4038, 2008
32. Kabata T, Matsumoto T, Yagishita S, et al: Vascular endothelial growth factor in rabbits during development of corticosteroid-induced osteonecrosis: A controlled experiment. J Rheumatol 35: 2383-2390, 2008